Loading...

Novo Integrated Sciences

OTCPK:NVOS
Snowflake Description

Moderate growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NVOS
OTCPK
$389M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

Novo Integrated Sciences, Inc., together with its subsidiaries, provides primary healthcare services. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
  • Novo Integrated Sciences has significant price volatility in the past 3 months.
NVOS Share Price and Events
7 Day Returns
2.8%
OTCPK:NVOS
3.2%
US Healthcare
3.2%
US Market
1 Year Returns
386.8%
OTCPK:NVOS
0.1%
US Healthcare
-6.5%
US Market
NVOS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Novo Integrated Sciences (NVOS) 2.8% -7.5% -11.9% 386.8% - -
US Healthcare 3.2% 8.5% -3.2% 0.1% 37.4% 89%
US Market 3.2% 11.4% -1.4% -6.5% 42.1% 41.6%
1 Year Return vs Industry and Market
  • NVOS outperformed the Healthcare industry which returned 0.1% over the past year.
  • NVOS outperformed the Market in United States of America which returned -6.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

NVOS Value

 Is Novo Integrated Sciences undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Novo Integrated Sciences. This is due to cash flow or dividend data being unavailable. The share price is $1.85.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Novo Integrated Sciences's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Novo Integrated Sciences's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:NVOS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-11-30) in USD $-0.01
OTCPK:NVOS Share Price ** OTCPK (2019-01-18) in USD $1.85
United States of America Healthcare Industry PE Ratio Median Figure of 53 Publicly-Listed Healthcare Companies 20.39x
United States of America Market PE Ratio Median Figure of 3,026 Publicly-Listed Companies 17.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Novo Integrated Sciences.

OTCPK:NVOS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:NVOS Share Price ÷ EPS (both in USD)

= 1.85 ÷ -0.01

-193.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Novo Integrated Sciences is loss making, we can't compare its value to the US Healthcare industry average.
  • Novo Integrated Sciences is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Novo Integrated Sciences's expected growth come at a high price?
Raw Data
OTCPK:NVOS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -193.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
62.9%per year
United States of America Healthcare Industry PEG Ratio Median Figure of 42 Publicly-Listed Healthcare Companies 1.54x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.29x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Novo Integrated Sciences, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Novo Integrated Sciences's assets?
Raw Data
OTCPK:NVOS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-11-30) in USD $0.00
OTCPK:NVOS Share Price * OTCPK (2019-01-18) in USD $1.85
United States of America Healthcare Industry PB Ratio Median Figure of 90 Publicly-Listed Healthcare Companies 2.47x
United States of America Market PB Ratio Median Figure of 5,101 Publicly-Listed Companies 1.77x
OTCPK:NVOS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:NVOS Share Price ÷ Book Value per Share (both in USD)

= 1.85 ÷ 0.00

699.96x

* Primary Listing of Novo Integrated Sciences.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Novo Integrated Sciences is overvalued based on assets compared to the US Healthcare industry average.
X
Value checks
We assess Novo Integrated Sciences's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. Novo Integrated Sciences has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NVOS Future Performance

 How is Novo Integrated Sciences expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Novo Integrated Sciences, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
62.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Novo Integrated Sciences expected to grow at an attractive rate?
  • Novo Integrated Sciences's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Novo Integrated Sciences's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Novo Integrated Sciences's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:NVOS Future Growth Rates Data Sources
Data Point Source Value (per year)
OTCPK:NVOS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 62.9%
United States of America Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 16.4%
United States of America Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 8.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.6%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:NVOS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:NVOS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-11-30 9 -1 -2
2018-08-31 9 -1 -2
2018-05-31 9 -1 -2
2018-02-28 9 -1 -2
2017-11-30 8 -1 -1
2017-08-31 8 -1 -1
2017-05-31 8 -1 -1
2017-02-28 7 -1 0
2016-11-30 7 -0 -0
2016-08-31 7 0 -0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Novo Integrated Sciences's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Novo Integrated Sciences is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:NVOS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Novo Integrated Sciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:NVOS Past Financials Data
Date (Data in USD Millions) EPS *
2018-11-30 -0.01
2018-08-31 -0.01
2018-05-31 -0.01
2018-02-28 -0.01
2017-11-30 -0.01
2017-08-31 -0.00
2017-05-31 -0.00
2017-02-28
2016-11-30 -0.00
2016-08-31 -0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Novo Integrated Sciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Novo Integrated Sciences's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Novo Integrated Sciences has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NVOS Past Performance

  How has Novo Integrated Sciences performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Novo Integrated Sciences's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Novo Integrated Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Novo Integrated Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Novo Integrated Sciences's 1-year growth to the US Healthcare industry average as it is not currently profitable.
Earnings and Revenue History
Novo Integrated Sciences's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Novo Integrated Sciences Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:NVOS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-11-30 8.95 -2.00 5.07
2018-08-31 8.89 -2.11 4.99
2018-05-31 8.94 -2.24 4.99
2018-02-28 8.71 -2.37 4.89
2017-11-30 8.40 -1.05 3.52
2017-08-31 7.96 -0.74 3.09
2017-05-31 7.58 -0.53 2.79
2017-02-28 7.37 0.01 2.43
2016-11-30 7.27 -0.16 2.41
2016-08-31 7.18 -0.34 2.39
2015-08-31 7.47 -1.58 2.99

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Novo Integrated Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Novo Integrated Sciences has efficiently used its assets last year compared to the US Healthcare industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Novo Integrated Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Novo Integrated Sciences's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Novo Integrated Sciences has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NVOS Health

 How is Novo Integrated Sciences's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Novo Integrated Sciences's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Novo Integrated Sciences's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Novo Integrated Sciences's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Novo Integrated Sciences's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Novo Integrated Sciences Company Filings, last reported 1 month ago.

OTCPK:NVOS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-11-30 0.52 2.65 0.93
2018-08-31 0.17 2.72 0.68
2018-05-31 0.28 2.73 0.86
2018-02-28 0.35 2.54 1.04
2017-11-30 -4.38 6.97 1.30
2017-08-31 -4.29 7.35 1.90
2017-05-31 -4.55 6.97 1.67
2017-02-28 -7.12 6.54 0.10
2016-11-30 -7.09 6.88 0.11
2016-08-31 -7.09 6.88 0.11
2015-08-31 -6.69 6.33 0.07
  • Novo Integrated Sciences's level of debt (511.1%) compared to net worth is high (greater than 40%).
  • Unable to establish if Novo Integrated Sciences's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Novo Integrated Sciences has sufficient cash runway for 1.2 years based on current free cash flow.
  • Novo Integrated Sciences has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 13.6% each year.
X
Financial health checks
We assess Novo Integrated Sciences's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Novo Integrated Sciences has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NVOS Dividends

 What is Novo Integrated Sciences's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Novo Integrated Sciences dividends.
If you bought $2,000 of Novo Integrated Sciences shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Novo Integrated Sciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Novo Integrated Sciences's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:NVOS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 1.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1986 Stocks 2.6%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.9%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Novo Integrated Sciences has not reported any payouts.
  • Unable to verify if Novo Integrated Sciences's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Novo Integrated Sciences's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Novo Integrated Sciences has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Novo Integrated Sciences's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Novo Integrated Sciences afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Novo Integrated Sciences has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NVOS Management

 What is the CEO of Novo Integrated Sciences's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rob Mattacchione
TENURE AS CEO 0.3 years
CEO Bio

Mr. Robert Mattacchione also known as Rob is Chairman of the Board and Chief Executive Officer at Novo Integrated Sciences, Inc. since October 2018. He is the co-founder of Novo Healthnet Limited, a wholly owned subsidiary of the Company ("NHL"). NHL was founded in 2013 to provide multi-dimensional primary healthcare services and products throughout Canada. Novo Integrated Sciences acquired NHL in 2017. For more than 25 years, Mr. Mattacchione has been a private venture investor leading the development of operational business interests worldwide, including the exploration and production of natural resources in Europe and South America, pharmaceutical product development and manufacturing in Africa and Europe, and renewable energy development and production in South America. From start-up to acquisition, Mr. Mattacchione formulates adaptive strategies, analyzes processes, engages highly-qualified personnel and provides the company vision and leadership throughout the ever changing and expanding landscape of business development.

CEO Compensation
  • Insufficient data for Rob to compare compensation growth.
  • Insufficient data for Rob to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Novo Integrated Sciences management team in years:

1.7
Average Tenure
45.5
Average Age
  • The average tenure for the Novo Integrated Sciences management team is less than 2 years, this suggests a new team.
Management Team

Chris David

TITLE
President & Director
COMPENSATION
$578K
AGE
59
TENURE
1.7 yrs

Rob Mattacchione

TITLE
Chairman of the Board & CEO
TENURE
0.3 yrs

Klara Radulyne

TITLE
Principal Financial Officer
AGE
40
TENURE
1.7 yrs

Emily Mattacchione

TITLE
Executive VP of Administration & Human Resource and Treasurer
AGE
36

David Brien

TITLE
Senior Vice President of Clinical Operations - Eastern Ontario

Mike Gaynor

TITLE
Secretary & Director
AGE
51
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the Novo Integrated Sciences board of directors in years:

1.7
Average Tenure
51
Average Age
  • The average tenure for the Novo Integrated Sciences board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chris David

TITLE
President & Director
COMPENSATION
$578K
AGE
59
TENURE
1.7 yrs

Rob Mattacchione

TITLE
Chairman of the Board & CEO
TENURE
0.3 yrs

Mike Gaynor

TITLE
Secretary & Director
AGE
51
TENURE
1.7 yrs

Pierre Dalcourt

TITLE
Director
AGE
47
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Novo Integrated Sciences's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Novo Integrated Sciences has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NVOS News

Simply Wall St News

NVOS Company Info

Map
Description

Novo Integrated Sciences, Inc., together with its subsidiaries, provides primary healthcare services. The company offers physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, chiropodist, neurological functions, kinesiology, concussion management and baseline testing, women’s pelvic health, sports medicine therapy, assistive devices, and private personal training services. It also operates 16 owned clinics, 88 contracted clinics, and 234 eldercare centric homes located in Canada. The company is headquartered in Bellevue, Washington. Novo Integrated Sciences, Inc. is a subsidiary of Mattacchione Family Trust.

Details
Name: Novo Integrated Sciences, Inc.
NVOS
Exchange: OTCPK
Founded:
$389,377,982
210,474,585
Website: http://www.novointegrated.com
Address: Novo Integrated Sciences, Inc.
11120 NE 2nd Street,
Suite 200,
Bellevue,
Washington, 98004,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK NVOS Common Stock Pink Sheets LLC US USD 10. May 2017
Number of employees
Current staff
Staff numbers
86
Novo Integrated Sciences employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/01/23 00:45
End of day share price update: 2019/01/18 00:00
Last earnings filing: 2019/01/11
Last earnings reported: 2018/11/30
Last annual earnings reported: 2018/08/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.